Drug Updates
New Drugs
New Indications
Patient Teaching
News Capsules
Drug Warnings
Herbal Spotlight
Quik Tools
Drug Info
Links
Drug Info Bookstore
Feedback
Disclaimer
|
|
 degarelix |
| trade name to be determined |
Pharmaceutical
company:
Ferring Pharmaceuticals, Inc.
www.degarelix.us |
Pharmacologic classification: GnRH receptor antagonist
Therapeutic classification: antineoplastic
Pregnancy risk category: X
AVAILABLE FORMS
Injection: 80-mg, 120-mg vials
INDICATIONS AND DOSAGES
Advanced prostate cancer—
Men: Initially, 240 mg subcutaneously administered as two 120-mg injections. Maintenance dose, 80 mg subcutaneously every 28 days.
CONTRAINDICATIONS AND CAUTIONS
Contraindicated in women who are or may become pregnant and in those who are hypersensitive to the drug or its components.
Use cautiously in patients with congenital long QT syndrome, electrolyte abnormalities, or heart failure and in those taking Class IA or Class III antiarrhythmics.
INTERACTIONS
Drug-drug.
Class IA, Class III antiarrhythmics (quinidine, procainamide, amiodarone, sotalol): May prolong QT interval. Avoid use together.
ADVERSE REACTIONS
CNS: asthenia, dizziness, fatigue, fever, headache, insomnia, nausea.
CV: hypertension.
GI: constipation, diarrhea.
GU: erectile dysfunction, urinary tract infection, testicular atrophy.
Metabolic: weight gain, increased GGT.
Musculoskeletal: arthralgia, back pain, decrease in bone density.
Skin: injection site reactions (including pain, erythema, swelling, induration, and nodule), night sweats, hyperhidrosis.
Other: chills, gynecomastia, hot flash.
Reactions may be common, uncommon, life-threatening,
or COMMON AND LIFE-THREATENING.
|
